Phathom Pharmaceuticals (PHAT) News Today $11.64 +0.59 (+5.34%) Closing price 04:00 PM EasternExtended Trading$12.00 +0.36 (+3.09%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 7.8% - Here's What HappenedOctober 6 at 6:21 PM | marketbeat.comPhathom Pharma Appoints Sanjeev Narula as CFOOctober 6 at 12:26 PM | marketwatch.comPhathom appoints Sanjeev Narula as chief financial, business officerOctober 6 at 12:26 PM | msn.comPhathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business OfficerOctober 6 at 8:00 AM | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 5.5% - Still a Buy?September 30, 2025 | marketbeat.comBrokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $17.50September 29, 2025 | americanbankingnews.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by BrokeragesSeptember 26, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) adds US$64m to market cap in the past 7 days, though investors from five years ago are still down 67%September 24, 2025 | finance.yahoo.comPhathom Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key BenchmarkSeptember 23, 2025 | msn.comGoldman Sachs Group Inc. Cuts Stake in Phathom Pharmaceuticals, Inc. $PHATSeptember 22, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.1% - Here's What HappenedSeptember 16, 2025 | marketbeat.comFDA Letters Flag Oprah Video, Morgan Freeman Ad in CrackdownSeptember 16, 2025 | msn.comWoodline Partners LP Decreases Stake in Phathom Pharmaceuticals, Inc. $PHATSeptember 15, 2025 | marketbeat.com596,108 Shares in Phathom Pharmaceuticals, Inc. $PHAT Bought by Jacobs Levy Equity Management Inc.September 12, 2025 | marketbeat.comPhathom Pharmaceuticals: The IP Question Is Answered, But Can Management Deliver (Rating Upgrade)September 8, 2025 | seekingalpha.comNuveen LLC Makes New $637,000 Investment in Phathom Pharmaceuticals, Inc. $PHATSeptember 6, 2025 | marketbeat.com683 Capital Management LLC Grows Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 4, 2025 | marketbeat.comRussell Investments Group Ltd. Purchases Shares of 41,799 Phathom Pharmaceuticals, Inc. $PHATSeptember 3, 2025 | marketbeat.comPropel Bio Management LLC Has $7.12 Million Stock Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 2, 2025 | marketbeat.comWellington Management Group LLP Raises Stock Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 2, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D FilingAugust 20, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 4.4% - Still a Buy?August 16, 2025 | marketbeat.comPhathom Pharmaceuticals (PHAT) Gets a Buy from GuggenheimAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) Gets a Buy from H.C. WainwrightAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comPhathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In LineAugust 9, 2025 | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | insidermonkey.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 11.7% Higher - Here's What HappenedAugust 8, 2025 | marketbeat.comPhathom (PHAT) Q2 Revenue Jumps 441%August 8, 2025 | theglobeandmail.comPhathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growthAugust 8, 2025 | msn.comPhathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comPhathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Rating of "Buy" by BrokeragesAugust 7, 2025 | marketbeat.comXTX Topco Ltd Invests $565,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)August 7, 2025 | marketbeat.comCraig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)August 6, 2025 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) to Release Earnings on ThursdayAugust 1, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7% - Here's WhyJuly 29, 2025 | marketbeat.comPhathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025July 28, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.2% Higher - Here's WhyJuly 26, 2025 | marketbeat.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells 1,692 Shares of StockJuly 19, 2025 | marketbeat.comRobert Charles Breedlove Sells 1,692 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockJuly 19, 2025 | insidertrades.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6% - Should You Sell?July 15, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Buy" from BrokeragesJuly 13, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.4% - Here's What HappenedJuly 7, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.4% - Here's WhyJuly 1, 2025 | marketbeat.comPhathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New MechanismJune 25, 2025 | seekingalpha.comPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - MorningstarJune 24, 2025 | morningstar.comMPhathom Pharmaceuticals, Inc. (PHAT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.com Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.440.77▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼64▲PHAT Articles Average Week Get the Latest News and Ratings for PHAT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Phathom Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NewAmsterdam Pharma News Viking Therapeutics News Amneal Pharmaceuticals News Centessa Pharmaceuticals News Xenon Pharmaceuticals News CG Oncology News uniQure News Ultragenyx Pharmaceutical News Apellis Pharmaceuticals News Immunovant News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
